Xunwei Jun (Unknown Microbe) Named to Deloitte's China Rising Star Awards and Files IPO Prospectus

Recently, the 20th Annual Conference of 2024"Deloitte China Rising Star"(Referred to as "Rising Stars") list was officially announced. This list is dedicated to discovering high-tech enterprises that are growing vigorously and continuously innovating, and is acclaimed by the industry as "the benchmark for globally high-growth enterprises." Xbiome successfully made it to the list with its microbiome research and industrial transformation achievements driven by cutting-edge technologies such as artificial intelligence.

Note: This chart only displays part of the list.
To view the complete list, please click on "Read Original" at the end of the article.

Deloitte introduced that the Deloitte Technology Fast series selection project was founded in Silicon Valley in 1995, entered China in 2005, and is held annually in dozens of countries and regions. Many industry leaders have emerged in the annual rankings, such as: Tencent, Alibaba, Baidu, JD.com, SMIC, WuXi AppTec, ByteDance, Apple, Microsoft, Google, Tesla, NVIDIA, etc. Companies are usually in the early stage when selected, and the ranking is also known as"The Cradle of Great Technology Enterprises"The theme of this year's project is "Pursuing Innovation and Quality, Beyond Growth".Emphasize that companies should focus more on innovation and high-quality development, strengthen the application of AI technology and talent development, balance short-term and long-term interests, and promote sustainable development.

Over the past year, Xbiome has focused on innovative microbiota scientific research and industrial transformation, achieving remarkable results. In terms of scientific research, Xbiome has continuously delivered innovative strains and actively filed patents with the help of its AI microbiome research and industrial transformation platform. Multiple research achievements have been published in globally renowned academic journals. Currently, Xbiome has two microbiota drug pipelines that have advanced to Phase II clinical trials, with pharmaceutical research progress ranking among the forefront in China; among them are genetically engineered microbial drugs like AUP-1602. The rapid transformation, implementation, application, and commercialization of AI and synthetic biology cutting-edge technologies are the core competitiveness driving Xbiome’s rapid development.

In terms of industrial direction, Xbiome continuously enriches its list of patented functional strains through the output of its technology platform. In 2024, Xbiome will carry out diverse industrial collaborations with several leading probiotic-related companies in and outside China, including strain licensing, joint development, and OEM manufacturing. In line with China's regulatory rules, Xbiome is developing more precise FMT (fecal microbiota transplantation) solutions to address unmet clinical needs for critical diseases and provide health services targeting mid-to-high-end sub-healthy populations. Xbiome will also expand nationwide commercial cooperation with publicly listed pharmaceutical enterprises, rapidly moving into the commercial expansion phase.

Moreover, over the past year, Xbiome's R&D investment and revenue have ranked among the top tier in the industry. The company’s healthy, robust, and sustainable business operations left a deep impression on the judging panel. After nearly half a year of evaluation, Xbiome successfully made it onto the "Deloitte China Rising Star" list.

"Deloitte China's National Leader of the High Growth Program, Zhao Jindong, introduced: 'This year’s program theme is "Pursuing Innovation and Quality, Beyond Growth." The global industrial landscape is evolving rapidly, with shortlisted companies focusing more on innovation and high-quality development. The unveiling of the list is both an endpoint and a starting point, as continuous innovation and seeking growth have become a common consensus in the business community.'"

-End-